|
業務類別
|
Biotechnology |
|
業務概覽
|
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors. |
| 公司地址
| 18 Campus Boulevard, Suite 100, Newtown Square, PA, USA, 19073 |
| 電話號碼
| +1 628 277-4836 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.arrivent.com |
| 員工數量
| 77 |
| Mr. Winston Kung, M.B.A. |
Chief Financial Officer, Principal Accounting Officer and Treasurer |
美元 492.42K |
28/04/2026 |
| Dr. Zhengbin Yao, PhD |
President, Chairman of Board and Chief Executive Officer |
美元 596.67K |
28/04/2026 |
| Dr. Stuart Lutzker, M.D.,PhD |
Director and President, Research and Development |
美元 515.78K |
28/04/2026 |
| Mr. James Paul Kastenmayer, J.D.,PhD |
General Counsel and Secretary |
-- |
28/04/2026 |
| Ms. Robin LaChapelle, M.D. |
Chief Operating Officer |
-- |
28/04/2026 |
|
|
| Dr. John A. Hohneker, M.D. |
Independent Director |
28/04/2026 |
| Mr. Christian W. Nolet, C.P.A. |
Independent Director |
28/04/2026 |
| Dr. Zhengbin Yao, PhD |
President, Chairman of Board and Chief Executive Officer |
28/04/2026 |
| Dr. Stuart Lutzker, M.D.,PhD |
Director and President, Research and Development |
28/04/2026 |
| Dr. Merdad V. Parsey, M.D.,PhD |
Independent Director |
28/04/2026 |
| Ms. Kristine Peterson |
Lead Independent Director |
28/04/2026 |
| Dr. James I. Healy, M.D.,PhD |
Independent Director |
28/04/2026 |
|
|
|
|
